NR2F6 and breast carcinoma: Previous studies have also shown increased NR2F6 expression in leukemia patients [10], breast cancer with poor prognosis [25], cervical cancer with pelvic lymph node metastasis and poor prognosis [7], and chemotherapy-resistant ovarian cancer [5].